The Singapore Clinical Research Institute (SCRI) is a national academic research organisation dedicated to enhancing the standards of human clinical research.
As a wholly-owned subsidiary of MOH Holdings, we strive to improve patient care through the design and conduct of cutting-edge clinical research. The highly experienced scientists and operations team at SCRI works closely with our partners, including leading pharmaceutical, medical devices and biotech, as well as academic Investigators.
Many of our research scientists hold joint appointments as university teaching faculty. SCRI endeavours to develop core capabilities and scientific expertise through conducting clinical research training programmes for research professionals.
SCRI collaborates with clinicians to develop specific disease and practice-focused Clinical Research Networks. Through the unique fusion of scientific leadership and operational excellence, SCRI offers a comprehensive suite of clinical research capabilities.
Today, SCRI is also involved in optimising Singapore’s clinical trial landscape through developing numerous National Clinical Trial Coordination Initiatives.
SCRI was restructured from the Clinical Trials & Epidemiology Research Unit (CTERU) in 2008.
The CTERU was founded in November 1996 by the Ministry of Health (MOH) with funding from the National Medical Research Council (NMRC) to provide infrastructure support for public-sector research. CTERU carried out multi-centre clinical trials, epidemiological and evidence-based medicine studies pegged at international standards.